Clinical Trials Logo

Relapsing Multiple Sclerosis clinical trials

View clinical trials related to Relapsing Multiple Sclerosis.

Filter by:

NCT ID: NCT00726648 Completed - Clinical trials for Relapsing Multiple Sclerosis

CDP323 Biomarker Study

Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

NCT ID: NCT00642902 Terminated - Clinical trials for Relapsing Multiple Sclerosis

Atacicept in Multiple Sclerosis, Phase II

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces Central Nervous System inflammation in subjects with RMS as assessed by frequent MRI. This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.

NCT ID: NCT00619307 Completed - Clinical trials for Relapsing Multiple Sclerosis

Transition to Rebif New Formulation

TRANSFER
Start date: July 2007
Phase: Phase 3
Study type: Interventional

To assess patient satisfaction with respect to the incidence of flu-like symptoms (FLS) in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly) to the new formulation of Rebif (RNF) while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurence of flu-like symptoms.

NCT ID: NCT00472797 Completed - Clinical trials for Relapsing Multiple Sclerosis

Rebif New Formulation (RNF) Quality of Life (QOL) Study

RebiQoL
Start date: April 2007
Phase: Phase 3
Study type: Interventional

To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).